Articles tagged with Prostate Cancer
A Mayo Clinic study has found that a baseline PSA test in men aged 40-60 can predict the risk of subsequent and low-risk prostate cancer. The study, which followed over 600 men for prostate outcomes, showed that men with elevated PSA levels were more likely to undergo biopsies and be diagnosed with low-risk cancer.
A University of Rochester analysis found that older men are more likely to die from prostate cancer due to late-stage diagnosis. The study's lead author notes that overall health plays a significant role in life expectancy following a cancer diagnosis.
Researchers discovered a gene has opposite effects in prostate and breast cancers, promoting growth when 'on' or 'off'. This finding suggests treating prostate and breast cancers requires distinct strategies, with blocking AR effective for prostate cancer but supporting AR production for breast cancer.
A large national study has found that men taking a daily vitamin E supplement face an increased risk of prostate cancer. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) tracked over 35,000 men and found a 17 percent higher incidence of prostate cancer in those taking the supplement.
A study of over 35,000 men found that daily vitamin E supplementation was associated with a significantly increased risk of developing prostate cancer. The researchers observed a 17% higher rate of prostate cancer detection in the vitamin E group compared to the placebo group.
A new NIH-funded study shows that taking high doses of vitamin E daily increases the risk of developing prostate cancer. Compared to a placebo group, men who took vitamin E supplements had 11 more cases of prostate cancer per 1,000 men over a seven-year period.
Researchers will explore molecular changes in prostate cancer progression to therapy resistance using cutting-edge technologies like molecular imaging and ultra-high throughput DNA sequencing.
A study by Fox Chase researchers found that a portion of the prostate bed is outside IMRT treatment margins in post-prostatectomy patients, suggesting too little treatment in the target area and too much in surrounding structures. The Calypso system helps ensure precise delivery within narrow treatment margins.
Researchers found that patients with a family history of prostate cancer had equivalent PSA controls, freedom from metastasis, and overall survival following radiotherapy. This suggests that more aggressive treatment may not be necessary for these patients.
Fox Chase researchers have developed a new nomogram that uses factors like PSA level, Gleason score, and interval to biochemical failure to estimate a patient's five- and 10-year risk of death. The tool helps doctors identify patients at highest risk of dying from prostate cancer.
Researchers at the University of Cincinnati have developed a method to isolate and collect fragile prostate cancer cells using inertial microfluidic technology. The approach uses cell size for separation, eliminating the need for biological markers or external forces.
A study found that men treated with IMRT had 26% fewer late bowel and rectal side effects than those receiving 3D-CRT. The treatment also showed a statistically significant decrease in acute toxicity.
A study found that men over 75 with prostate cancer are being undertreated, while those with a single comorbid condition are being overtreated. The study suggests that individual medical problems impact survival more than age alone.
A new study found that couples counseling can significantly improve the sex lives of prostate cancer survivors and their spouses. The therapy was shown to be effective in improving men's sexual function and satisfaction, as well as enhancing their partner's experience.
Research at the University of Texas MD Anderson Cancer Center found that couples counseling significantly improves sexual satisfaction and function for prostate cancer survivors and their partners. Internet-based sexual counseling was shown to be equally effective as traditional sex therapy.
A team of Seattle researchers has mapped the genome of advanced prostate cancers, identifying 'hypermutation' as a key driver of disease progression and potential resistance to therapies. The study provides clues for early detection and new therapeutic strategies.
A randomized trial found that a shorter radiation course for prostate cancer with hypofractionation is as effective as conventional radiation therapy at five years after treatment. The study used intensity modulated radiotherapy (IMRT) to limit dose to normal tissues, reducing side effects.
A phase III clinical trial shows that abiraterone acetate significantly improves fatigue in men with metastatic castration-resistant prostate cancer. The treatment also delays the progression of fatigue and has a potential survival benefit.
Researchers have developed a new bone-targeting drug that can delay the onset of metastases in hormone-resistant prostate cancer patients. The study showed that denosumab prolonged bone metastasis-free survival significantly compared to placebo, improving patient quality of life.
Two new risk indicators for prostate cancer have been identified, showing an association between benign prostatic hyperplasia and an increased risk of developing and dying from prostate cancer. Elevated prostate-specific antigen (PSA) levels in healthy men also predict long-term risk of developing prostate cancer.
A study by Johns Hopkins researchers found a significant rise in serious prostate biopsy complications requiring hospitalization among Medicare beneficiaries. Hospital admission rates were two-fold higher among those who underwent a biopsy compared to controls, with infection-related complications on the rise since 2000.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a gene-based imaging system that can detect castration-resistant prostate cancer earlier than conventional methods. The system uses specific genes and reporter genes to accurately identify the spread of the disease, giving oncologists more time to treat it and pot...
A recent study published in JAMA found that discussing sexuality with doctors can improve quality of life for prostate cancer survivors. Researchers used phone interviews and questionnaires to measure quality of life in over 2,900 men before and after treatment, including surgery, radiation, or brachytherapy. The study revealed that me...
Researchers developed prediction models that accurately predict erectile function after prostate cancer treatment based on pretreatment sexual function and patient characteristics. The models found that men who underwent certain treatments had a higher chance of regaining functional erections suitable for intercourse.
Research suggests that genetic variations in mRNA and microRNA play a critical role in prostate cancer disparities between African-American and white men. The findings could lead to more specialized treatment options for African-American patients.
Researchers found that high calcium intake increases prostate cancer risk among African-American men genetically predisposed to poor calcium absorption. This study provides insight into the link between diet and disease, suggesting personalized prevention strategies may be possible in the future.
A study by USC researchers suggests that high dietary intake of calcium causes prostate cancer among African-American men genetically good at absorbing the mineral. Men with poor calcium absorption were less likely to develop advanced prostate cancer.
Researchers aim to determine optimal Vitamin C dosing schedule and test therapy in septic patients to moderate organ dysfunction and improve outcomes. A potential new treatment for sepsis may be on the horizon thanks to a significant grant.
A team of researchers has identified five genetic variants that play a key role in the progression and mortality of prostate cancer. The discovery could lead to the development of a simple blood test to determine which patients need aggressive treatment versus conservative care.
A new urine-based test has been found to be more accurate than traditional prostate cancer screening methods, detecting the disease in 100% of cases while minimizing false positives. The PSA/SIA assay works by analyzing changes in PSA protein structure associated with cancer.
Researchers found that PHLPP1 and PTEN tumor suppressor genes work together to prevent lethal prostate cancer. The study suggests that monitoring gene transcription activity could predict patient outcomes and identify best candidates for clinical trials.
Researchers at Lund University have developed a new treatment option for advanced prostate cancer by targeting cancer stem cells with a STAT3-inhibitor. The study found that galiellalactone, a natural compound, has inhibitory effects on the growth of prostate cancer cells and prevents tumour growth and spreading.
Researchers at Beth Israel Deaconess Medical Center are receiving $1 million each from the Prostate Cancer Foundation to develop a vaccine that boosts patients' immune systems against prostate cancer. The goal of this treatment is to directly attack prostate-cancer cells and potentially be less expensive and more easily disseminated.
Researchers discovered a DNA biomarker, GSTP1, in bodily fluids that can complement the PSA test to increase prostate cancer diagnosis accuracy. The new blood test may reduce unnecessary biopsies and provide physicians with reassurance about biopsy recommendations.
A new urine test can help identify men at high risk of clinically significant prostate cancer, potentially delaying or avoiding needle biopsies. The test supplements an elevated PSA screening result and combines genetic markers to predict cancer presence.
Researchers have identified a new hormonal pathway driving advanced prostate cancer, which can be targeted by drugs. This discovery will help develop accurate biomarkers and improve treatment outcomes for resistant tumors.
Scientists have developed a tiny fiber-optic biosensor to detect elevated PSA levels in cases of breast cancer. The biosensor's sensitivity and specificity are comparable to those found in current screening methods for breast cancer.
A new study published in the New England Journal of Medicine found that combining short-term hormone therapy (ADT) with radiation therapy significantly improves overall survival rates for men with intermediate-risk prostate cancer. The treatment also resulted in a 10% reduction in disease-specific deaths among high-risk patients.
Researchers identified seven new DNA variants associated with increased prostate cancer risk, accounting for 25% of familial cancer risk. The study, conducted by an international consortium, used genome-wide association studies to identify genetic variants linked to the disease.
A recent study published in BJUI found that homosexual men taking bicalutamide for prostate cancer reported significant reductions in all aspects of their sexual functioning and satisfaction, ranging from 23% to 54%. In contrast, heterosexual men reported fewer problems and were more satisfied with intercourse.
A new study from Harvard School of Public Health and University of California, San Francisco, found that men with prostate cancer who smoke are at higher risk of disease recurrence and mortality. Smoking was also associated with more aggressive disease at diagnosis.
A study found that men diagnosed with prostate cancer who are also smokers have an increased risk of dying from prostate cancer, as well as all-cause and cardiovascular disease mortality. Smoking cessation after diagnosis did not significantly impact mortality risks compared to never-smokers.
Researchers found that prostate cancer can adapt to hormone therapy by activating a survival cell signaling pathway, making it more effective. The study's findings suggest that targeting both the androgen receptor and PI3K pathways may be necessary to effectively treat these cancers.
Scientists at Oregon State University have confirmed the safety and cancer-targeting ability of sulforaphane in a new study. Sulforaphane selectively kills cancer cells while leaving healthy prostate cells untouched, suggesting it could be used for cancer prevention and treatment.
A multi-site study has shown that the new drug Cabozantinib is effective in treating prostate cancer that has spread to the bone, with three-quarters of patients experiencing partial or complete tumor shrinkage. Additionally, patients showed significant improvements in bone pain and reduced need for narcotic use.
A prospective study found that smoking significantly increases a woman's risk for peripheral artery disease (PAD), which can cause pain and discomfort. The study also suggests that smoking cessation reduces the risk, but even after 20 years of abstention, the risk remains elevated.
A new targeted therapy, G-1, has been shown to halt the growth of tumors in animals with advanced prostate cancer resistant to hormone therapy. The treatment works by targeting and activating protein GPR30, which sensitizes tumor cells to its inhibiting effects.
Men with prostate cancer treated with hormone deprivation therapy may be at increased risk of developing diabetes or metabolic syndrome. According to the study, men in the ADT group had a twofold increased probability of having diabetes compared to those who did not receive hormonal therapy.
A multicenter clinical trial found stereotactic body radiation therapy (SBRT) to be an effective treatment option for patients with localized prostate cancer, delivering results in just five 30-minute sessions. The study's findings suggest that higher doses of radiation are safe and can lead to improved outcomes.
Researchers found that itraconazole can delay the progression of prostate cancer and reduce PSA levels, with 48.4% of patients experiencing stable or declining PSA after high-dose treatment. The antifungal also disrupted a key cancer-initiating biological pathway called Hedgehog.
A new experimental vaccine made from frozen immune cells has shown promise in extending the survival of metastatic prostate cancer patients. The vaccine, APC8015F, was found to increase median survival by approximately 10 months compared to those not treated with it.
A new study shows that abiraterone acetate, a life-extending pill for advanced prostate cancer, prolongs survival by about four months compared to placebo. The medication also reduces PSA blood levels in patients with the disease.
A recent study found that men who walk briskly after diagnosis have a 57% lower rate of progression of disease than those who walk at an easy pace. Brisk walking can delay or even prevent progression of prostate cancer.
A study of 1,455 U.S. men with early-stage prostate cancer found that brisk walking lowers the risk of prostate cancer progression by nearly 60%. Regular physical activity can improve prognosis, and walking must be brisk for benefits to occur.
A new study by American Cancer Society researchers found that long-term regular acetaminophen use was associated with a 38% lower risk of prostate cancer. The study suggests that acetaminophen may provide biological clues about prostate cancer development, warranting further research.
A genome-wide association study found a novel risk variant on chromosome 17q21 that is common in African American men but rare in other populations. This discovery builds on previous research identifying a risk region on chromosome 8q24, suggesting a genetic contribution to racial disparities in prostate cancer risk.
A new study from the University of Michigan Comprehensive Cancer Center finds that half of prostate cancers have a genetic anomaly making them responsive to PARP inhibitors. These drugs are being tested in breast cancer patients and show promise in shrinking tumors and blocking cancer spread.
A new study shows that nearly 70% of men with rising PSA levels and subsequent normal biopsies were eventually diagnosed with prostate cancer. Rising PSA velocity over several years should prompt clinicians to follow patients more closely, even with negative biopsy results.
New studies released by ASCO highlight advances in cervical cancer screening, ovarian cancer detection, and prostate cancer risk prediction. The studies also explore genetic biomarkers for chemotherapy-induced neuropathy and potential treatments for relapsed ovarian cancer.
A large-scale study found that men who drink coffee regularly have a lower risk of developing lethal prostate cancer. The study, led by Harvard School of Public Health researchers, also showed that decaf and regular coffee both reduced the risk, with even moderate consumption offering significant protection.